David Bick

David Bick

Auto-generated profile, based on publicly available information

David Bick

HudsonAlpha Institute for Biotechnology, Huntsville, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2022 in npj Genomic Medicine
Verified
Journal Article
Open access
PDF file
CAChristina A. Austin-Tse
Christina A. Austin-Tse
VJVaidehi Jobanputra
Vaidehi Jobanputra
DPDenise L. Perry
Denise L. Perry
DBDavid Bick
David Bick
RTRyan J. Taft
Ryan J. Taft
MIMedical Genome Initiative
Medical Genome Initiative
Whole genome sequencing (WGS) shows promise as a first-tier diagnostic test for patients with rare genetic disorders. However, standards addressing the definition and deployment practice of a best-in-class test are lacking. To address these gaps, the Medical Genome Initiative, a consortium of leading health care and research organizations in the US and Canada, was formed to expand access to high quality clinical WGS by convening experts and publishing best practices. Here, we present best practice recommendations for the interpretation and reporting of clinical diagnostic WGS, including discussion of challenges and emerging approaches that will be critical to harness the full potential of this comprehensive test.

23 October 2020 in npj Genomic Medicine
Verified
Journal Article
Open access
PDF file
CMChristian R. Marshall
Christian R. Marshall
SCShimul Chowdhury
Shimul Chowdhury
RTRyan J. Taft
Ryan J. Taft
MLMatthew Lebo
Matthew Lebo
JBJillian G. Buchan
Jillian G. Buchan
MIMedical Genome Initiative
Medical Genome Initiative
Whole-genome sequencing (WGS) has shown promise in becoming a first-tier diagnostic test for patients with rare genetic disorders; however, standards addressing the definition and deployment practice of a best-in-class test are lacking. To address these gaps, the Medical Genome Initiative, a consortium of leading healthcare and research organizations in the US and Canada, was formed to expand access to high-quality clinical WGS by publishing best practices. Here, we present consensus recommendations on clinical WGS analytical validation for the diagnosis of individuals with suspected germline disease with a focus on test development, upfront considerations for test design, test validation practices, and metrics to monitor test performance. This work also provides insight into the current state of WGS testing at each member institution, including the utilization of reference and other standards across sites. Importantly, members of this initiative strongly believe that clinical WGS is an appropriate first-tier test for patients with rare genetic disorders, and at minimum is ready to replace chromosomal microarray analysis and whole-exome sequencing. The recommendations presented here should reduce the burden on laboratories introducing WGS into clinical practice, and support safe and effective WGS testing for diagnosis of germline disease.

25 April 2019 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
DBDavid Bick
David Bick
MJMarilyn Jones
Marilyn Jones
STStacie L Taylor
Stacie L Taylor
RTRyan J Taft
Ryan J Taft
JBJohn Belmont
John Belmont
Up to 350 million people worldwide suffer from a rare disease, and while the individual diseases are rare, in aggregate they represent a substantial challenge to global health systems. The majority of rare disorders are genetic in origin, with children under the age of five disproportionately affected. As these conditions are difficult to identify clinically, genetic and genomic testing have become the backbone of diagnostic testing in this population. In the last 10 years, next-generation sequencing technologies have enabled testing of multiple disease genes simultaneously, ranging from targeted gene panels to exome sequencing (ES) and genome sequencing (GS). GS is quickly becoming a practical first-tier test, as cost decreases and performance improves. A growing number of studies demonstrate that GS can detect an unparalleled range of pathogenic abnormalities in a single laboratory workflow. GS has the potential to deliver unbiased, rapid and accurate molecular diagnoses to patients across diverse clinical indications and complex presentations. In this paper, we discuss clinical indications for testing and historical testing paradigms. Evidence supporting GS as a diagnostic tool is supported by superior genomic coverage, types of pathogenic variants detected, simpler laboratory workflow enabling shorter turnaround times, diagnostic and reanalysis yield, and impact on healthcare.

1 May 2017 in Genetics in Medicine
Verified
Journal Article
Closed access
PDF file
JOJulianne O'Daniel
Julianne O'Daniel
HMHeather M. McLaughlin
Heather M. McLaughlin
LALaura M. Amendola
Laura M. Amendola
SBSherri J. Bale
Sherri J. Bale
JBJonathan S. Berg
Jonathan S. Berg
HHeidi Rehm
Heidi Rehm

15 December 2020 in npj Genomic Medicine
Verified
Journal Article
Open access
PDF file
RHRobin Hayeems
Robin Hayeems
DDDavid Dimmock
David Dimmock
DBDavid Bick
David Bick
JBJohn W. Belmont
John W. Belmont
RGRobert C. Green
Robert C. Green
MIMedical Genome Initiative
Medical Genome Initiative
Whole-genome sequencing (WGS) is positioned to become one of the most robust strategies for achieving timely diagnosis of rare genomic diseases. Despite its favorable diagnostic performance compared to conventional testing strategies, routine use and reimbursement of WGS are hampered by inconsistencies in the definition and measurement of clinical utility. For example, what constitutes clinical utility for WGS varies by stakeholder’s perspective (physicians, patients, families, insurance companies, health-care organizations, and society), clinical context (prenatal, pediatric, critical care, adult medicine), and test purpose (diagnosis, screening, treatment selection). A rapidly evolving technology landscape and challenges associated with robust comparative study design in the context of rare disease further impede progress in this area of empiric research. To address this challenge, an expert working group of the Medical Genome Initiative was formed. Following a consensus-based process, we align with a broad definition of clinical utility and propose a conceptually-grounded and empirically-guided measurement toolkit focused on four domains of utility: diagnostic thinking efficacy, therapeutic efficacy, patient outcome efficacy, and societal efficacy. For each domain of utility, we offer specific indicators and measurement strategies. While we focus on diagnostic applications of WGS for rare germline diseases, this toolkit offers a flexible framework for best practices around measuring clinical utility for a range of WGS applications. While we expect this toolkit to evolve over time, it provides a resource for laboratories, clinicians, and researchers looking to characterize the value of WGS beyond the laboratory.

22 December 2020 in American Journal of Medical Genetics Part C: Seminars in Medical Genetics
Verified
Journal Article
Open access
PDF file
DBDavid Bick
David Bick
SBSarah L. Bick
Sarah L. Bick
DDDavid P. Dimmock
David P. Dimmock
TFTom A. Fowler
Tom A. Fowler
MCMark J. Caulfield
Mark J. Caulfield
RSRichard H. Scott
Richard H. Scott
More than 4,000 genes have been associated with recognizable Mendelian/monogenic diseases. When faced with a new diagnosis of a rare genetic disorder, health care providers increasingly turn to internet resources for information to understand the disease and direct care. Unfortunately, it can be challenging to find information concerning treatment for rare diseases as key details are scattered across a number of authoritative websites and numerous journal articles. The website and associated mobile device application described in this article begin to address this challenge by providing a convenient, readily available starting point to find treatment information. The site, Rx-genes.com (https://www.rx-genes.com/), is focused on those conditions where the treatment is directed against the mechanism of the disease and thereby alters the natural history of the disease. The website currently contains 633 disease entries that include references to disease information and treatment guidance, a brief summary of treatments, the inheritance pattern, a disease frequency (if known), nonmolecular confirmatory testing (if available), and a link to experimental treatments. Existing entries are continuously updated, and new entries are added as novel treatments appear in the literature.